What is it about?
This is the first report of a probiotic stopping brain atrophy in an MCI population. This randomized, double-blind placebo-controlled study conducted in a Japanese MCI population living in Japan aimed to gain as much information as possible on the cognitive enhancement potential of Bifidobacterium breve (MCC1274). For this study, we used MMSE and ADAS-Jcog to assess the improvement of cognitive functions by the probiotic strain. Participants underwent MRI to determine brain atrophy changes using Voxel-based Specific Regional Analysis System for Alzheimer’s disease (VSRAD).
Featured Image
Photo by Steven HWG on Unsplash
Why is it important?
In this a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial, significant improvement of “Orientation” was seen in cognitive test by Probiotic Bifidobacterium breve (MCC1274) intake. Probiotics consumption for 24 weeks suppressed brain atrophy progression, suggesting that B. breve MCC1274 helps prevent cognitive impairment of MCI subjects.
Perspectives
If this article helps the elucidation of the brain-gut correlation, I am happy.
Daisuke Asaoka
Gakko Hojin Juntendo
Read the Original
This page is a summary of: Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Alzheimer’s Disease, June 2022, IOS Press,
DOI: 10.3233/jad-220148.
You can read the full text:
Contributors
The following have contributed to this page
